Status:
COMPLETED
Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)
Lead Sponsor:
AstraZeneca
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18+ years
Brief Summary
This a non-interventional multi-centre study to evaluate the symptom load and management strategies in PPI-treated GERD patients with persistent GERD symptoms..
Eligibility Criteria
Inclusion
- Provision of informed consent
- Subjects with a diagnosis of GERD and with predominant typical GERD symptoms: heartburn/regurgitation
- Subjects who fail to obtain satisfactory symptomatic response after their first full course (4-8 weeks) of standard dose PPI (once a day)
Exclusion
- Inability to read and/or understand Patient Reported Outcomes questionnaires
- Subjects where the only reason for the visit is renewing the prescription
- A history of an incomplete response to PPI treatment prior to current course of treatment
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
2674 Patients enrolled
Trial Details
Trial ID
NCT00768443
Start Date
September 1 2008
End Date
February 1 2009
Last Update
December 7 2010
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bjelovar, Croatia
2
Research Site
Bulinec, Croatia
3
Research Site
Crikvenica, Croatia
4
Research Site
Daruvar, Croatia